1-Benzyl-4-pivaloylpiperazine | 224309-92-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Benzyl-4-pivaloylpiperazine
• 英文别名: 1-(4-Benzylpiperazin-1-yl)-2,2-dimethylpropan-1-one
• CAS: 224309-92-6
• 化学式: C₁₆H₂₄N₂O
• mdl: MFCD00862227
• 分子量: 260.379
• InChiKey: ZNSNSDXYPRJFJH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.562
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME
  申请人：ABIDE THERAPEUTICS, INC.

  公开号：US20190202801A1

  公开（公告）日：2019-07-04

  Provided herein are piperazine carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or ABHD6. Furthermore, the subject compounds and compositions are useful for the treatment of pain.

  本文提供了哌嗪氨基甲酸酯和包含该化合物的药物组合物。所述化合物和组合物可用作MAGL和/或ABHD6的调节剂。此外，所述化合物和组合物可用于治疗疼痛。
• Nicotinamide Derivatives
  申请人：Katsifis Andrew

  公开号：US20110178396A1

  公开（公告）日：2011-07-21

  A compound comprising a pyridine carboxamide structure, for use in imaging or treating melanoma, is described. An aromatic ring in the structure is substituted with a radiohalogen atom and the substitution on the amide nitrogen atom is such that the compound binds to melanin.

  描述了一种含有吡啶羧酰胺结构的化合物，用于成像或治疗黑色素瘤。结构中的芳香环被取代为一个放射性卤原子，酰胺氮原子上的取代使得该化合物与黑色素结合。
• COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE
  申请人：SHY Therapeutics LLC

  公开号：US20170174699A1

  公开（公告）日：2017-06-22

  Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.

  本文提供了抑制MAPK磷酸化的化合物，因此可用于治疗癌症和炎症性疾病的组合物和方法。
• PYRIMIDINES, TRIAZINES AND THEIR USE AS PHARMACEUTICAL AGENTS
  申请人：Wang Shudong

  公开号：US20110092490A1

  公开（公告）日：2011-04-21

  A compound of formula (I) and its pharmaceutically acceptable salts or solvates and physiologically hydrolysable, solubilising or immobilisable derivatives wherein: Ar is a 5-membered heteroaryl ring wherein X 1 and X 2 are one or two heteroatoms or Ar is a 6-membered aromatic ring, wherein heteroatoms are selected from S, O, N, Se; Z is NH, NHCO, NHSO 2 , N-alkyl, CH 2 NH, CH 2 N-alkyl, CH 2 , CH 2 CH 2 , CH═CH, CH 2 CONH, SO 2 , or SO; Y is N CR 3 ; R 1 , R 2 , R 5 , R 6 , R 7 , R 8 and R 9 are each independently H, or a substituent; R 3 , when present, is selected from alkyl and a substituent, with the proviso that when Y is CR 3 , Ar is a 5-membered heterocycle comprising one or two N heteroatoms and Z is NH, then R3 is selected from C 3+ alkyl and a substituent; R 4 is selected from H, alkyl and R 13 as hereinbefore defined, with the proviso that when R 3 is absent, R 4 is selected from alkyl and a substituent; processes for the preparation thereof, intermediates and precursors therefore and the use thereof as a medicament, and therapeutic compositions comprising the compound.

  化合物式（I）及其药学上可接受的盐或溶剂化合物和生理水解、溶解或固定化衍生物，其中：Ar是一个5元杂环芳基环，其中X1和X2是一个或两个杂原子，或Ar是一个6元芳香环，其中杂原子选自S、O、N、Se；Z是NH、NHCO、NHSO2、N-烷基、CH2NH、CH2N-烷基、CH2、CH2CH2、CH═CH、CH2CONH、SO2或SO；Y是N CR3；R1、R2、R5、R6、R7、R8和R9各自独立地为H或取代基；R3在存在时，选自烷基和取代基，但当Y为CR3，Ar为一个包含一个或两个N杂原子的5元杂环，并且Z为NH时，R3选自C3+烷基和取代基；R4选自H、烷基和如上所述的R13，但当R3不存在时，R4选自烷基和取代基；其制备方法、中间体和前体以及作为药物的用途和包含该化合物的治疗组合物。
• Optical active 1,4-dihydropyridine compounds as bradykinin antagonists
  申请人：PFIZER INC.

  公开号：EP0899261A1

  公开（公告）日：1999-03-03

  This invention provides a compound of the formula (I): and its pharmaceutically acceptable salts, wherein A1 and A2 are each halo; R1 and R2 are independently C1-4 alkyl; R3 is substituted or unsubstituted, phenyl or naphthyl; Y is heterocyclic group selected from C5-10 azacycloalkyl, C6-10 diazacycloalkyl, C7-10 azabicycloalkyl and the like; and R4 is selected from (a) substituted or unsubstituted C1-8 alkyll; (b) substituted or unsubstituted amino; (c) substituted or unsubstituted C2-6 alkanoyl; (d) substituted or unsubstituted C3-8 cycloalkyl or C7-14 bicycloalkyl; (e) substituted or unsubstituted C5-10 azacycloalkyl or C6-10 diazacycloalkyl, and (f) substituted or unsubstituted C7-14 mono- or di-azabicycloalkyl. These compounds are useful for the treatment of medical conditions caused by bradykinin such as inflammation, cardiovascular disease, pain, etc. This invention also provides a pharmaceutical composition comprising the above compound, and intermediates of the above compounds.

  本发明提供了一种式（I）化合物： 及其药学上可接受的盐类，其中 A1 和 A2 各为卤代；R1 和 R2 独立地为 C1-4 烷基；R3 为取代或未取代的苯基或萘基；Y 为杂环基团，选自 C5-10 氮杂环烷基、C6-10 二氮杂环烷基、C7-10 氮杂双环烷基等；R4 选自 (a) 取代或未取代的 C1-8 烷基；(b) 取代或未取代的氨基； (c) 取代或未取代的 C2-6 烷酰基； (d) 取代或未取代的 C3-8 环烷基或 C7-14 双环烷基； (e) 取代或未取代的 C5-10 氮杂环烷基或 C6-10 二氮杂环烷基，以及 (f) 取代或未取代的 C7-14 单氮杂双环烷基或双氮杂双环烷基。这些化合物可用于治疗由缓激肽引起的病症，如炎症、心血管疾病、疼痛等。本发明还提供了一种药物组合物，其中包含上述化合物以及上述化合物的中间体。